ATC | B/G | Ingredients | code | Registration Nb | Name | Dosage | Presentation | Form | Route | Agent | Laboratory | Country | Price | Pharmacist Margin | Stratum | Responsible Party Name | Responsible Party Country | Exch_date | %SUBSIDY |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
L01DB01 | B | Doxorubicin HCl pegylated liposomes - 20mg/10ml | 11020/388 | 40122/1 | CAELYX | 20mg/10ml | 1 x 10ml | Injectable concentrated solution | Infusion | Abela Frères S.A.L. | Janssen Pharmaceutica NV | Belgium | L.L | 19.35 | D | Baxter Holding BV | The Netherlands | 2/5/2024 |
ATC | B/G | Ingredients | code | Registration Nb | Name | Dosage | Presentation | Form | Route | Agent | Laboratory | Country | Price | Pharmacist Margin | Stratum | Responsible Party Name | Responsible Party Country | Exch_date | %SUBSIDY |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
L01DB01 | B | Doxorubicin HCl pegylated liposomes - 20mg/10ml | 11020 | 40122/1 | CAELYX | 20mg/10ml | 1 x 10ml | Injectable concentrated solution | Infusion | Abela Frères S.A.L. | Janssen Pharmaceutica NV | Belgium | 32,513,227 L.L | 19.35 | D | Baxter Holding BV | The Netherlands | 2/5/2024 | 0 |